MUNDIPHARMA has announced the acquisition of the exclusive rights for Invossa-K, a non-surgical gene therapy for osteoarthritis pain from Kolon Life Sciences.
The deal covers a range of territories including Australia and New Zealand, along with Singapore, Malaysia, the Philippines, Thailand, Vietnam, Indonesia and Myanmar.
Mundipharma also has rights to the product in the UAE, Saudi Arabia, Japan and Korea, where it was first approved by the Korean Ministry of Drug Safety in 2017.
Invossa-K is an intra-articular injection offering sustained pain reduction and functional improvement for a year following a single treatment, based on a US Phase II clinical trial, as well as a Phase III trial conducted in Korea.
Mundipharma CEO Raman Singh said the firm would now go through the process of conducting trials and getting Invossa-K approved in the additional territories.
"It is very satisfying to think of the millions of patients who will benefit from this revolutionary medicine in the near future," he said.
Invossa-K is a 3:1 mixture of normal human chondroocytes (hChonJ) and human chondrocytes transduced with the human TGF-1 gene (hChonJb#7) which works by polarising macrophage to M2 macrophage, which has an immune-regulatory function by producing Interleukin-10, thereby improving the articular immune environment to contribute to self-recovery of a joint.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jan 19
